Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a

Table 1 Demographic details, treatment outcomes based on virologic responses, viral load at baseline and serial serum samples analysed over time for HCV genotype 3a chronically infected patients

Patient Group	Type of Response	Sex	Rx Naïve	Age (years) at Baseline	Viral Load log₁₀ IU/ml at Baseline	Time points
						Pre treatment period		Early treatment period				Post treatment period
Sustained virological response (SVR)				Mean Age 41 ± 12	Mean VL 5.66 ± 0.66	E	B	W1	W2	W3	W4	L
SVR3	SVR	F	Yes	28	5.47	+	+	+	+	+	- (V)	TND
SVR6	SVR	F	Yes	35	5.16	+	+	- (V)	TND	TND	TND	TND
SVR7	SVR	F	Yes	32	5.46	+	+	+	- (V)	TND	TND	TND
SVR8	SVR	F	Yes	59	6.89	+	+	+	NA	NA	+ (V)	TND
SVR9	SVR	F	No	45	6.37	+	+	+	+	NA	- (V)	TND
SVR12	SFR	F	Yes	49	5.17	+	+	TND	TND	TND	TND	TND
Treatment failure (TF)				Mean Age 41 ± 7	Mean VL 6.23 ± 0.63	E	B	W1	W2	W4	W12*	L
NR2	NR	F	Yes	42	5.05	+	+	+	NA	+	+	+ (W3)
R1	R	M	Yes	46	7.5	+	+	+ (V)	TND	TND	TND	+ (W2)
R4	R	M	Yes	45	7.11	+	+	+	+ (V)	TND	TND	+ (W10)
R13	R	M	Yes	31	6.32	+	+	+	-	TND	TND	- (W12)

The pre treatment period corresponds to E and B time point. E for early sample, taken between 6 to 12 months before treatment and B for baseline sample, taken at day 0 of pegylated INF-α2a/ribavirin treatment. The early treatment period corresponds to W1 to W4 time points (samples taken at 1, 2, 3 or 4 weeks of treatment). The sample taken at week 12 of treatment was only available for the non-responder patient (W12*). The post treatment period corresponds to the L time point and was only available within the TF group. L for late sample taken at 2, 3, 10 or 12 weeks after the end of treatment). +, sample available with successful analysis. -, sample available with unsuccessful analysis. TND, target not detected when HCV RNA was not detectable in the sample. (V), sample treated with the Viraffinity™ reagent. NA, sample non available for analysis.

ISSN: 1743-422X